Evogene (NASDAQ:EVGN) Stock Crosses Below 200 Day Moving Average – Should You Sell?

Evogene Ltd. (NASDAQ:EVGN)’s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $1.18 and traded as low as $1.04. Evogene shares last traded at $1.10, with a volume of 573,151 shares changing hands.

Evogene Trading Down 1.8%

The stock has a market cap of $5.80 million, a price-to-earnings ratio of -2.16 and a beta of 1.35. The stock’s 50 day moving average is $1.06 and its two-hundred day moving average is $1.18.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, November 20th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.10. Evogene had a negative net margin of 52.33% and a negative return on equity of 75.09%. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.65 million.

Institutional Trading of Evogene

An institutional investor recently raised its position in Evogene stock. Jane Street Group LLC boosted its stake in shares of Evogene Ltd. (NASDAQ:EVGN) by 58.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,732 shares of the biotechnology company’s stock after acquiring an additional 12,387 shares during the quarter. Jane Street Group LLC owned about 0.63% of Evogene worth $42,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.